Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Elmed Eisai Conducts PMS on 2 of Its Generic Products
August 6, 2007
-
ARCHIVE Kissei Enters into Agreement with Nuon Therapeutics on Rizaben
August 6, 2007
-
ARCHIVE GENERICS NEWS IN BRIEF
August 6, 2007
-
ARCHIVE Mitsubishi Tanabe to Start Domestic Sales with 15 Branches, 142 Business Offices
August 6, 2007
-
ARCHIVE Transnasal Endoscopy IT Forum to Start Full-Scale Activities
August 6, 2007
-
ARCHIVE NEW PRODUCTS/Flivas OD Tablet 75 mg: Asahi Kasei Pharma
August 6, 2007
-
ARCHIVE Incidence of Nasal Bleeding 6% in Transnasal Endoscopy
August 6, 2007
-
ARCHIVE Nippon Kayaku to Consolidate Its Position as Specialty Pharma Focusing on Oncology
August 6, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
August 6, 2007
-
ARCHIVE Astellas, Pfizer Initiate Campaign on Prevention of Arteriosclerosis
August 6, 2007
-
ARCHIVE Use IT to More Effectively Use Patients' Data: AstraZeneca President Dr Kato
August 6, 2007
-
ARCHIVE Korosho Wants to See 1/4-1/3 of World's New Drugs Developed in Japan: New Industry Vision
August 6, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 6, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
August 6, 2007
-
ARCHIVE New Nycomed to Go Global through Partnering
August 6, 2007
-
ARCHIVE Makers' Accountability Essential to Implement JPMA's Proposal: FPMAJ President
August 6, 2007
-
ARCHIVE Exelon Skin Patch Recommended for European Approval: Novartis
August 6, 2007
-
ARCHIVE Metronidazole-Based 3-Drug Combination to Be Approved for Hp Eradication
August 6, 2007
-
ARCHIVE MD Studies to Be Permitted at a Total Dose of 500 μg: Dr Ohno
July 30, 2007
-
ARCHIVE TOPICS/Mebix Starts Home Blood Pressure Management Service
July 30, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…